Ignaty Leshchiner

Associate Professor in Computational Medicine, Boston University School of Medicine

GitHub

iglc

Google Scholar

Ignaty Leshchiner is an Associate Professor in Computational Biomedicine at the Boston University School of Medicine. His research is focused on method development and computational analysis of cancer genomic data and specifically on tumor heterogeneity, progression and treatment evasion.

Selected Lab Papers

Inferring early genetic progression in cancers with unobtainable premalignant disease

Leshchiner I, Mroz EA, Cha J, [...], Getz G, Rocco JW
Nature Cancer (2023).
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer

Ravi A, Hellmann MD, Arniella MB, [...], Hacohen N, Getz G, Gainor JF
Nature Genetics (2023).
Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome

Parry EM, Leshchiner I, Guièze R, [...], Stilgenbauer S, Getz G, Wu CJ
Nature Medicine (2023).
Pirtobrutinib Targets BTK C481S in Ibrutinib-Resistant CLL but Second-Site BTK Mutations Lead to Resistance

Naeem A, [...], Zain R, Smith CIE, Leshchiner I, Parida L, Getz G, Brown JR
Blood Advances (2022).
Clinical Efficacy and Whole Exome Sequencing of Liquid Biopsies in a Phase IB/II study of Bazedoxifene and Palbociclib in Hormone Receptor-Positive Breast Cancer

Tsuji J, [...], Getz G, Jeselsohn R
Clinical Cancer Research (2022).
Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma

Freeman SS, Sade-Feldman M, [...], Getz G, Hacohen N
Cell Reports Medcine 3 (2) (2022).
Parallel Genomic Alterations of Antigen and Payload Targets mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer

Coates JT, Sun S, [...], Bardia A, Ellisen LW
Cancer Discovery 11 (10) 2436-2445 (2021).
Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes

Dentro SC, Leshchiner I, Haase K, Tarabichi M, Wintersinger J, Deshwar AG, Yu K, Rubanova Y, Macintyre G, Demulemeester J, [...], Wang W, Morris QD, Wedge DC, Van Loo P
Cell 184 (8) 2239-2254 (2021).
Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression

Busteros M, Sklavenitis-Pistofidis R, [...], Manier S, Getz G, Ghobrial IM
Journal of Clinical Oncology 38 (21) 2380-2389 (2020).
The evolutionary history of 2,658 cancers

Gerstung M, Jolly C, Leshchiner I, Dentro SC, Gonzalez S, [...], Spellman P, Wedge D, Van Loo P
Nature 578 (7793) 122-128 (2020).
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers

Parikh AR, Leshchiner I, Elagina L, [...], Getz G, Corcoran RB
Nature Medicine 25 (9) 1415-1421 (2019).
Growth dynamics in naturally progressing chronic lymphocytic leukaemia

Gruber M, Bozic I, Leshchiner I, Livitz D, [...], Getz G, Wu CJ
Nature 570 (7762) 474-479 (2019).
Comprehensive analysis of tumour initiation, spatial and temporal progression under multiple lines of treatment

Leshchiner I, Livitz D, Gainor J, Rosebrock D, [...], Shaw A, Getz G
bioRxiv (2019).
Comment on "DNA damage is a pervasive cause of sequencing errors, directly confounding variant identification"

Stewart C, Leshchiner I, [...], Getz G
Science 361 (6409) (2018).
Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in Hürthle Cell Carcinoma

Gopal RK, Kübler K, [...], Getz G, McFadden DG
Cancer Cell 34 (2) 242-255.e5 (2018).
Distinct mutational signatures characterize concurrent loss of polymerase proofreading and mismatch repair

Haradhvala NJ, Kim J, Maruvka YE, [...], Mouw KW, Lawrence MS, Getz G
Nature Communications 9 (1) 1746 (2018).
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes

Chapuy B, Stewart C, Dunford AJ, [...], Getz G, Shipp MA
Nature Medicine 24 (5) 679-690 (2018).
Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors

Adalsteinsson VA, Ha G, Freeman SS, [...], Getz G, Love JC, Meyerson M
Nature Communications 8 (1) 1324 (2017).
Resolving the phylogenetic origin of glioblastoma via multifocal genomic analysis of pre-treatment and treatment-resistant autopsy specimens

Brastianos PK, Nayyar N, Rosebrock D, Leshchiner I, [...], Cahill DP, Getz G, Batchelor TT
Precision Oncology 1 (1) (2017).
A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer

Polak P, Kim J, Braunstein LZ, [...], Foulkes WD, Getz G
Nature Genetics 49 (10) 1476-1486 (2017).
Comprehensive assessment of cancer missense mutation clustering in protein structures

Kamburov A, [...], Lander ES, Getz G
PNAS 112 (40) E5486-95 (2015).